Thursday, January 19, 2017

UPDATE 1-Bristol won't seek faster Opdivo, Yervoy lung cancer drug approvals

Jan 19 (Reuters) - Bristol-Myers Squibb Co on

Thursday said it has decided not to seek accelerated U.S.

approval for its combination of two immunotherapy drugs as an

initial treatment for lung cancer.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)